李可欣,常莎莎,邸东华,修敬雅
LI Ke-xin,CHANG Sha-sha,DI Dong-hua,XIU Jing-ya

• 1:沈阳药科大学药学院
• 2:辽宁中医药大学药学院

摘要(Abstract)：

目的对配体介导的纳米脂质体作为肿瘤疫苗载体的可行性进行评价。方法建立体外树突状细胞(dendritic cells,DC)模型,考察DC对配体介导纳米脂质体的摄取行为;建立S180荷瘤鼠模型,考察配体介导纳米脂质体对荷瘤鼠的免疫效果。结果 DEC205单克隆抗体介导的纳米脂质体能被DC细胞特异性识别,提高摄取效率,同时也能显著抑制肿瘤生长,延长小鼠存活时间,在整个免疫周期内均能保持较高的IL-12和IFN-γ水平,对S180荷瘤鼠具有明显的免疫治疗作用。结论配体介导的纳米脂质体能够产生有效的抗肿瘤免疫应答,可以作为治疗型肿瘤疫苗的载体。
Objective To investigate the feasibility evaluation of ligand-mediated nanoliposomes as carries of anti-tumor vaccine.Methods In vitro dendritic cells(DC) cells model was established to investigate uptake behavior of DC cells,and the mice model bearing S180 cancer tumorwas established to evaluate the antitumor immune effect.Results DEC205 Mc Ab mediated nanoliposomes were readily taken up by dendritic cells,and could significantly inhibit tumor growth,prolong the survival time of mice and maintain a high level of IL-12 and IFN-r in all immune period.Conclusions Ligand-mediated nanoliposomes can enhance the anti-tumor immune response and can be used as carriers of anti-tumor vaccines.

关键词(KeyWords)： 配体介导;纳米脂质体;肿瘤疫苗;可行性评价
ligand-mediated;nanoliposomes;anti-tumor vaccine;feasibility evaluation

Abstract:

Keywords:

基金项目(Foundation): 辽宁省教育厅一般资助项目(L2014383);; 国家自然科学基金资助项目(81302721)

作者(Author): 李可欣,常莎莎,邸东华,修敬雅
LI Ke-xin,CHANG Sha-sha,DI Dong-hua,XIU Jing-ya

DOI: 10.14066/j.cnki.cn21-1349/r.2017.01.004

参考文献(References)：

• [1]BERNHARD F,DOLORES J S.Third generation dendritic cell vaccines for tumor immunotherapy[J].European Journal of Cell Biology,2012,91(1):53-58.
• [2]MASATO K,YUTARO N,TAKAFUMI S,et al.Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell(DC)vaccine[J].Vaccine,2012,30(16):2633-2639.
• [3]SAMAR H,AZITA H,RYAN W H.Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations[J].Advanced Drug Delivery Reviews,2011,63(10/11):943-955.
• [4]AYUMI Y,XIN G,SEIJI T.Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system[J].Journal of Controlled Release,2010,142(3):411-415.
• [5]UMUT G,LUISA M P.Influence of the mannose receptor in host immune responses[J].Immunobiology,2009,214(7):554-561.
• [6]LI K X,CHANG S S,WANG Z Y,et al.A novel microemulsion and micelle assembling methodtoprepareDEC205 monoclonal antibody coupled cationic nanoliposomes forsimulating exosomes to target dendritic cells[J].International Journal of Pharmaceutics,2015,491:105-112.
• [7]YANG S Y,ZHENG Y,CHEN J Y.Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection[J].Colloids and Surfaces B:Biointerfaces,2013,101:6-13.
• [8]LI H,PIAO L Z,YU B.Delivery of calf thymus DNA to tumor by folate receptortargeted cationicliposomes[J].Biomaterials,2011,32:6614-6620.
• [9]THONUR L,HAIGD M,THOMSON J,et al.Toll-like receptor gene expression in fresh and archived ovine pseudoafferent lymph DEC205+dendritic cells[J].Journal of Comparative Pathology,2012,147(2/3):296-304.
• [10]PARK S H,KYIN T,BENDELAC A,et al.The contribution of NKT cells,NK cells,and otherγ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors[J].The Journal of Immunology,2003,170(3):1197-1201.
• [11]SOFIE D,LAETITIA C,ISABEL V A,et al.Combination of interleukin-12 gene therapy,metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication[J].Journal of Controlled Release,2014,187:175-182.
• [12]LIN S,CHANG H,LEKHA N,et al.Interleukin 12(IL-12)family cytokines:role in immune pathogenesis and treatment of CNS autoimmune disease[J].Cytokine,2015,75(2):249-255.
• [13]ANNELIES R B,JOKE R,MARGARET C,et al.Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12[J].Vaccine,2009,27(5):701-707.
• [14]GRI G,CHIODONI C,GALLO E,et al.Antitumor effect of interleukin(IL)-12 in the absence of endogenous IFN-γa role for intrinsic tumor immunogenicity and IL-15[J].Cancer Research,2002,62(15):4390-4397.
• [15]NORDLY P,AGGER E M,ANDERSEN P.Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes:physicochemical characterization and induction of CD8+T-cell responses in vivo[J].Pharmaceutical Research,2011,28:553-562.
• [16]NAKAMURA T,MORIGUCHI R,KOGURE K.Incorporation of polyinosinepolycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen,but not by octaarginine modified antigen complex[J].International Journal of Pharmaceutics,2013,441(1/2):476-481.